Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 305

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 8
Chunk 305
---
ities of investment securities555 55 1,530 Other, net189 13 774 Cash flows from investing activities(20,820)(2,009)(623)Cash flows from financing activitiesProceeds from issuance of other short-term borrowings5,008 — — Repayments of other short-term borrowings(5,008)— — Proceeds from issuance of long-term debt16,963 — 2,000 Repayments of long-term debt and finance lease obligations(9,613)(4,149)(14,433)Debt issuance costs(99)(38)— Dividends paid(11,025)(10,539)(10,043)Purchases of treasury stock(1,708)(1,972)(1,487)Proceeds from the exercise of stock options214 180 262 Payments of contingent consideration liabilities— (752)(1,132)Other, net57 48 30 Cash flows from financing activities(5,211)(17,222)(24,803)Effect of exchange rate changes on cash and equivalents(65)5 (62)Net change in cash and equivalents(7,290)3,613 (545)Cash and equivalents, beginning of year12,814 9,201 9,746 Cash and equivalents, end of year$5,524 $12,814 $9,201 Other supplemental informationInterest paid, net of portion capitalized$2,811 $2,469 $2,546 Income taxes paid4,064 4,702 2,988 

 The accompanying notes are an integral part of these consolidated financial statements.

55     |  2024 Form 10-K

AbbVie Inc. and Subsidiaries

Notes to Consolidated Financial Statements

Note 1 Background 

BackgroundThe principal business of AbbVie Inc. (AbbVie or the company) is the discovery, development, manufacturing and sale of a broad line of therapies that address some of the world's most complex and serious diseases. AbbVie's products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers from AbbVie-owned distribution centers and public warehouses. Certain products (including aesthetic products and devices) are also sold directly to physicians and other licensed healthcare providers. In the United States, AbbVie distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to retailers